Comparative Pharmacology
Head-to-head clinical analysis: PEDIAMYCIN 400 versus WYAMYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEDIAMYCIN 400 versus WYAMYCIN E.
PEDIAMYCIN 400 vs WYAMYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
400 mg orally every 6 hours for 10 days.
500 mg intramuscularly or intravenously every 12 hours; or 1 gram every 24 hours for severe infections.
None Documented
None Documented
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
2.5 hours (increased to 5-8 hours in neonates and up to 24-48 hours in anuria).
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Primarily renal (60-80% unchanged) via glomerular filtration; biliary/fecal <5%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic